MAR 16, 2017 9:25 AM PDT

3 Patients Lose Sight After Stem Cell Injections

WRITTEN BY: Carmen Leitch

Three women involved in an experimental study have lost their eyesight after their eyes were injected with stem cells. While the women found the clinical trial after seeing it on a government website, ClinicalTrials.gov, the study had no government endorsement. At the clinic, liposuction was used to harvest fat from the women’s bellies, ‘stem cells’ were extracted from that tissue and subsequently injected into the eyes of the patients. Because stem cells are not drugs, the clinic did not have to obtain FDA approval before using them.

While the three women had some visual impairment, prior to the procedure they were all able to see well enough to be able to drive. One of the women, aged 72, is now totally blind; the other two aged 78 and 88, have lost the majority of their eyesight.

The procedure and outcomes have been described in a New England Journal of Medicine (NEJM)article (not authored by the doctors that performed the procedures). The women suffered detached retinas, a problem that requires immediate surgery to stop blindness from happening, as a thin layer of cells that transmit light information from the eyeball to the brain breaks free of the back of the eye. The intense pressure on the eyes of one patient was probably around three times its normal level, and it caused damage to the optic nerves. She was blinded even though doctors tried to operate in time.

“The really horrible thing about this is that you would never, nobody practicing good medicine would ever do an experimental procedure on a patient on both eyes on the same day,” commented Dr. Thomas A. Albini to the New York Times. He met two of the patients at the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine.

He noted that standard procedure is to treat one eye at a time, preferably starting with the eye that is more impaired, and if something goes wrong the patient keeps some eye function. After a second patient showed up in his office, he called the FDA (who has not commented on this story because of an ongoing investigation).

Two of the patients sued the clinic, U.S. Stem Cell, and settled, but have signed non-disclosure agreements; the last patient did not comment. U.S. Stem Cell is now struggling financially, and no longer treats eyes, though they do still see patients for joint issues.

Many clinics promising big results from stem cell therapies have sprung up with little or no oversight. The FDA has approved only a very small number of trials involving stem cells, so it’s important for people to be wary of these clinics. One red flag: the women paid $5000 for their procedures. Legitimate, government-funded clinical trials don’t charge patients for participating.

The FDA warns people about the dangers of experimental, unregulated therapeutics on a webpage. The NEJM article also suggested adverse events from these tests go underreported since there is no reporting requirement.

A spokesperson for the NIH clarified the nature of the ClinicalTrials.gov website to the New York Times: “The information on ClinicalTrials.gov is provided by the study sponsor or principal investigator and posting on ClinicalTrials.gov does not necessarily reflect endorsement by the N.I.H. ClinicalTrials.gov does not independently verify the scientific validity or relevance of the trial itself beyond a limited quality control review.”

NEJM also published an accompanying article that seeks to clarify the benefits and risks of stem cell therapeutics.

Sources: New York Times, NEJM

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
OCT 24, 2022
Neuroscience
Frankenworld: Should We Be Afraid of Playing God or Failing To Love Our Monsters?
OCT 24, 2022
Frankenworld: Should We Be Afraid of Playing God or Failing To Love Our Monsters?
Lawyer Henry T. Greely analyzes the relevance of Mary Shelley's classic, "Frankenstein," in light of today's bioscience
SEP 30, 2022
Coronavirus
A New Kind of Antiviral Against SARS-CoV-2
SEP 30, 2022
A New Kind of Antiviral Against SARS-CoV-2
Scientists are developing a human version of a drug that was highly beneficial to a hamster model of COVID-19. The drug, ...
OCT 18, 2022
Genetics & Genomics
Mitochondrial DNA Can Move to the Genome to Trigger Human Evolution
OCT 18, 2022
Mitochondrial DNA Can Move to the Genome to Trigger Human Evolution
Mitochondria are often called the powerhouse of the cell, and these organelles are well-known for their energy-generatin ...
OCT 23, 2022
Immunology
The Double-Edged Sword of Iron Deficiency
OCT 23, 2022
The Double-Edged Sword of Iron Deficiency
Iron is a crucial nutrient. Most of the iron in the body is contained in red blood cells, as part of hemoglobin, which i ...
OCT 30, 2022
Neuroscience
Why Fear Memories Can Persist in the Brain
OCT 30, 2022
Why Fear Memories Can Persist in the Brain
People have to experience fear so they can learn to avoid dangerous situations. But some memories can be more persistent ...
NOV 28, 2022
Neuroscience
Experimental Drug Halts Deadly Brain Cancer Growth Without Harming Brain Cells
NOV 28, 2022
Experimental Drug Halts Deadly Brain Cancer Growth Without Harming Brain Cells
  Researchers have found that blocking a certain enzyme halts the growth of a childhood brain cancer tumor. The cor ...
Loading Comments...